Online inquiry

IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12455MR)

This product GTTS-WQ12455MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL2RB gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000878.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3560
UniProt ID P14784
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12455MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ16009MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ14635MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ14670MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ1583MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-083
GTTS-WQ11974MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MM-005
GTTS-WQ12397MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NI-0401
GTTS-WQ484MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ9014MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMC RON-8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW